Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001061857 | SCV001226616 | likely benign | Nemaline myopathy 2 | 2023-12-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004030438 | SCV004980817 | uncertain significance | Inborn genetic diseases | 2023-09-20 | criteria provided, single submitter | clinical testing | The c.12140G>A (p.R4047Q) alteration is located in exon 82 (coding exon 80) of the NEB gene. This alteration results from a G to A substitution at nucleotide position 12140, causing the arginine (R) at amino acid position 4047 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV004693552 | SCV005187944 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV001061857 | SCV001455266 | uncertain significance | Nemaline myopathy 2 | 2020-09-16 | no assertion criteria provided | clinical testing |